Lozicum1 mg

Lozicum 1 mg is a benzodiazepine indicated for the following uses:

Established / FDA-approved uses

• Anxiety disorders: short-term relief (generally not longer than 4 months) of the symptoms of anxiety, or anxiety associated with symptoms of depression.
• Status epilepticus: injectable Lozicum 1 mg is indicated for the treatment of status epilepticus, given intravenously by a healthcare professional.
• Preanesthetic sedation: injectable Lozicum 1 mg is used for sedation, relief of anxiety, and to produce a decreased ability to recall events related to surgery or unpleasant procedures, when given intramuscularly or intravenously prior to a procedure.

Commonly used off-label (not formally FDA-approved for this use)

• Short-term management of insomnia associated with anxiety.
• Alcohol withdrawal syndrome (adjunct, to control agitation, tremor, and prevent seizures).
• Adjunct antiemetic for chemotherapy-induced nausea and vomiting (used in combination with standard antiemetics).

Lozicum 1 mg is not indicated for the treatment of anxiety associated with everyday stress, and long-term use is generally not recommended.

Each formulation of Lozicum 1 mg contains Lozicum 1 mg as the active pharmaceutical ingredient. Lozicum 1 mg is available as oral tablets (commonly 0.5 mg, 1 mg, and 2 mg strengths) and as a sterile injectable solution for intramuscular or intravenous use. Exact strengths, dosage forms, and inactive ingredients vary by manufacturer; refer to the specific product label for full composition details.

Lozicum 1 mg is a synthetic benzodiazepine with anxiolytic, sedative, hypnotic, anticonvulsant, and skeletal muscle relaxant properties. It belongs to the intermediate-acting class of benzodiazepines, meaning its clinical effects have a moderate duration compared with shorter- or longer-acting agents in the same class.

Lozicum 1 mg is classified as a controlled substance due to its potential for dependence and abuse, and is intended for short-term, physician-supervised use in the management of anxiety and certain seizure and sedation indications.

Lozicum 1 mg belongs to the benzodiazepine class of medicines, specifically an intermediate-acting anxiolytic/sedative-hypnotic agent. It is chemically and pharmacologically distinct from barbiturates but shares a similar mechanism of central nervous system depression through enhancement of GABA activity.

Mechanism of Action

Lozicum 1 mg acts on the central nervous system by binding to a specific site on the GABA-A receptor complex, a ligand-gated chloride ion channel. This binding enhances the affinity of the inhibitory neurotransmitter gamma-aminobutyric acid (GABA) for its receptor, increasing the frequency of chloride channel opening. The resulting influx of chloride ions hyperpolarizes the neuronal membrane, reducing neuronal excitability. This produces the anxiolytic, sedative, anticonvulsant, and muscle-relaxant effects characteristic of Lozicum 1 mg and other benzodiazepines.

Pharmacokinetics

Lozicum 1 mg is well absorbed after oral administration, with peak plasma concentrations reached within about 2 hours. It has intermediate lipophilicity and undergoes hepatic conjugation (glucuronidation) to an inactive metabolite, which is renally excreted; unlike many other benzodiazepines, Lozicum 1 mg metabolism does not depend on the cytochrome P450 system, which reduces the likelihood of certain metabolic drug interactions. Its elimination half-life is approximately 10 to 20 hours in healthy adults.

Lozicum 1 mg oral tablets are taken by mouth, with or without food, exactly as directed by the prescribing physician. Injectable Lozicum 1 mg is administered intramuscularly or intravenously only by qualified healthcare personnel, with monitoring for excessive sedation and respiratory depression. Do not adjust the dose or frequency of Lozicum 1 mg without consulting a physician.

Clinically Significant Drug Interactions

• Opioids (Boxed Warning): Concomitant use of Lozicum 1 mg with opioid analgesics or opioid-containing cough/cold products can result in profound sedation, respiratory depression, coma, and death. Concomitant prescribing should be reserved for cases where alternatives are inadequate, using the lowest effective doses.
• Other CNS depressants (alcohol, barbiturates, other benzodiazepines, sedating antihistamines, general anesthetics, antipsychotics, other antidepressants): Additive central nervous system and respiratory depression; concurrent use should be avoided or closely monitored.
• Probenecid: May decrease the clearance and increase the plasma levels and effect of Lozicum 1 mg; a lower Lozicum 1 mg dose may be needed.
• Valproate: Can increase plasma concentrations of Lozicum 1 mg; dose adjustment may be required.
• Clozapine: Concurrent use with Lozicum 1 mg has been associated with marked sedation, excessive salivation, hypotension, and respiratory arrest in some patients; use with caution.

Always inform the physician or pharmacist of all other medicines being taken before starting Lozicum 1 mg.

The most common side effects of Lozicum 1 mg are related to central nervous system depression and include:

• Sedation and drowsiness (most common)
• Dizziness
• Weakness and unsteadiness (ataxia)
• Fatigue
• Disorientation or confusion, particularly in elderly patients

Less common effects include headache, blurred vision, nausea, changes in appetite, and skin rash. Rarely, paradoxical reactions such as agitation, irritability, or aggression can occur, especially in children and the elderly. Abrupt discontinuation after prolonged use can cause withdrawal symptoms (see Precautions and Warnings). Patients should report any unusual or severe side effects to their physician promptly.

Pregnancy

Lozicum 1 mg should be used during pregnancy only if clearly needed and the potential benefit justifies the potential risk to the fetus. Benzodiazepines, including Lozicum 1 mg, cross the placenta and use late in pregnancy or during labor has been associated with neonatal sedation, hypotonia ("floppy infant syndrome"), and withdrawal symptoms in the newborn. Lozicum 1 mg use during pregnancy should only occur under close medical supervision, and any decision should be made in consultation with a physician.

Lactation

Lozicum 1 mg is excreted in breast milk and may cause sedation, poor feeding, or weight loss in a breastfed infant. Breastfeeding while using Lozicum 1 mg is not generally recommended; a physician should be consulted to weigh the benefits of breastfeeding against the potential risk to the infant.

Dependence and Withdrawal

Prolonged use of Lozicum 1 mg can lead to physical and psychological dependence, even at recommended doses. Abrupt discontinuation after extended use may cause withdrawal symptoms, including anxiety rebound, tremor, insomnia, and, rarely, seizures. Lozicum 1 mg should be discontinued gradually under medical supervision, never stopped abruptly without consulting a physician.

Sedation and Fall Risk

Lozicum 1 mg can cause significant drowsiness and impaired coordination, increasing the risk of falls and injury, particularly in elderly patients. Patients should avoid driving or operating heavy machinery until they know how Lozicum 1 mg affects them.

Respiratory Depression

Lozicum 1 mg, especially the injectable form, can cause dose-dependent respiratory depression; caution is required in patients with pre-existing respiratory disease and when combined with other CNS depressants or opioids (see boxed warning under Contraindications/Interaction).

Tolerance and Abuse Potential

Lozicum 1 mg is a controlled substance with potential for misuse, abuse, and addiction. It should be used only as prescribed and not shared with others.

Lozicum 1 mg should be used at the lowest effective dose for the shortest duration consistent with treatment goals, and only as prescribed by a physician.

Overdose of Lozicum 1 mg may cause excessive drowsiness, confusion, slurred speech, impaired coordination, and, in severe cases, respiratory depression, coma, and death, particularly when combined with alcohol or other CNS depressants such as opioids.

If an overdose of Lozicum 1 mg is suspected, seek immediate medical attention or contact emergency services / a poison control center right away. Treatment is generally supportive (monitoring of airway, breathing, and circulation); do not attempt specific home treatment. A specific reversal agent (flumazenil) may be used by medical professionals in certain circumstances, but only under close medical supervision due to risks including seizures.

Store Lozicum 1 mg tablets at room temperature (below 30°C), protected from light and moisture. Keep out of reach of children. Injectable Lozicum 1 mg formulations may require refrigeration and protection from light per the specific manufacturer's instructions — check the product label. Do not use after the expiry date.

Elderly

Elderly patients are more sensitive to the sedative and psychomotor effects of Lozicum 1 mg and are at higher risk of falls, confusion, and respiratory depression. Lower starting doses are recommended, with careful titration.

Hepatic Impairment

Lozicum 1 mg does not require oxidative hepatic metabolism and is often better tolerated than other benzodiazepines in liver disease, but dose reduction and monitoring are still advised in significant impairment.

Renal Impairment

Use with caution; dose adjustment may be needed as the inactive glucuronide metabolite is renally excreted.

Pediatric Use

See Pediatric Uses section.

Oral Lozicum 1 mg for anxiety is generally recommended for short-term use, typically not exceeding 4 months, including any necessary tapering period, as efficacy for longer-term use has not been systematically evaluated and risk of dependence increases with duration. The need for continued treatment should be reassessed regularly by the prescribing physician. Duration for status epilepticus and preanesthetic use is determined by the treating physician in the acute care setting.

Lozicum 1 mg belongs to the benzodiazepine class of central nervous system depressants, further categorized as an intermediate-acting anxiolytic, sedative-hypnotic, and anticonvulsant agent.

Lozicum 1 mg enhances the inhibitory effect of the neurotransmitter GABA on the GABA-A receptor complex, increasing chloride ion influx into neurons. This hyperpolarizes neuronal membranes and reduces neuronal excitability throughout the central nervous system, producing anxiolytic, sedative, anticonvulsant, and muscle-relaxant effects.

D

The safety and efficacy of Lozicum 1 mg oral tablets for the management of anxiety have not been established in pediatric patients, and routine use in children for this indication is generally not recommended.

Injectable Lozicum 1 mg has been used under specialist supervision in pediatric status epilepticus and for procedural sedation, based on clinical guidelines and physician judgment, with dosing individualized by weight and age; this should only occur in a hospital setting under close monitoring for sedation and respiratory depression. Any pediatric use of Lozicum 1 mg should be directed and supervised by a physician experienced in pediatric care.